zosuquidar development code experimental antineoplastic zosquidir inhibits drugs mechanism include tariquidar laniquidar pglycoproteins transmembrane proteins pump foreign substances cells atp dependent fashion cancers overexpressing pglycoproteins able pump therapeutic molecules able reach target effectively making cancer multidrug resistant zosuquidar inhibits pglycoproteins inhibiting efflux pump restoring sensitivity chemotherapeutic zosuqidar initially characterized syntex corporation acquired roche roche licensed drug eli lilly granted orphan drug status fda aml announced phase iii clinical trial treatment acute myeloid leukemia aml myelodysplastic syndrome meet primary eli lilly discontinued httpsenwikipediaorgwikizosuquidar